Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eli Lilly

818.55
+0.53000.06%
Volume:1.92M
Turnover:1.58B
Market Cap:775.98B
PE:69.90
High:832.00
Open:822.76
Low:814.00
Close:818.02
Loading ...

Unusually active option classes on open April 17th

TIPRANKS
·
17 Apr

Stock Track | Eli Lilly Soars 14% on Breakthrough Oral Diabetes and Weight Loss Drug Trial Results

Stock Track
·
17 Apr

Eli Lilly Shares Soar 14% as Lilly Pill Leads To 7.9% Weight Loss In Late-Stage Trial

Reuters
·
17 Apr

Leerink bullish on Eli Lilly after ‘picture-perfect’ Phase 3 oral GLP-1 results

TIPRANKS
·
17 Apr

Eli Lilly Shares Soar After Phase 3 Trial Success for Oral Type 2 Diabetes Pill

GuruFocus
·
17 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Eli Lilly, Plug Power, Snap-On

Reuters
·
17 Apr

BRIEF-Bighat Biosciences And Lilly Collaborate To Advance Ai-Driven Antibody Therapeutics

Reuters
·
17 Apr

Bighat Biosciences and Lilly Collaborate to Advance AI-Driven Antibody Therapeutics

THOMSON REUTERS
·
17 Apr

Lilly's Weight-Loss Pill Shocks Wall Street

GuruFocus.com
·
17 Apr

BUZZ-Eli Lilly jumps as pill leads to 7.9% weight loss in late-stage trial

Reuters
·
17 Apr

Top Premarket Gainers

MT Newswires Live
·
17 Apr

BMO Capital Adjusts Eli Lilly Price Target to $900 From $1,010, Maintains Outperform Rating

MT Newswires Live
·
17 Apr

Morning Brew: Eli Lilly's Diabetes Drug Success Sends Shares Soaring

GuruFocus
·
17 Apr

Why Eli Lilly and Company (LLY) Is Among the Best Blue Chip Stocks to Buy According to Billionaires

Insider Monkey
·
17 Apr

Eli Lilly's stock soars as successful trial of weight-loss pill is a game changer

Dow Jones
·
17 Apr

Eli Lilly shares jump 12% on positive Phase 3 results for oral diabetes drug

Investing.com
·
17 Apr

Eli Lilly Shares Jump Premarket After First Pill for Diabetes, Weight Loss Shows Positive Study Results

Dow Jones
·
17 Apr

Palatin Technologies Inc - Phase 2 Trial Showed Significant Weight Loss With Bremelanotide and Tirzepatide

THOMSON REUTERS
·
17 Apr

Palatin Technologies Inc - Ind Filings Expected by End of Q4 2025

THOMSON REUTERS
·
17 Apr

Palatin Technologies Inc - Low-Dose Bremelanotide Prevented Appetite Rebound After Tirzepatide Cessation

THOMSON REUTERS
·
17 Apr